Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. (ALLO) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · ALLO · as of Sep 30, 2025
Ownership Breakdown
176
Institutional Holders
▲ 14 vs Q2
$201.52M
Total Inst. Value
▼ $6.42M vs Q2
243.87M
Shares Outstanding
freeFloat 66.53%
162.50M
13F Shares Held
▼ 21.49M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
ALLO largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
PFIZER INC biological products, (no diagnostic substances) | 22.03M | 10.06% | 10.06% | $27.32B | Nov 13, 2025 | — held |
TPG GP A, LLC biological products, (no diagnostic substances) | 18.72M | 8.55% | 8.55% | $23.21B | Nov 14, 2025 | — held |
BLACKROCK, INC. biological products, (no diagnostic substances) | 17.51M | 8.00% | 8.00% | $21.72B | Nov 12, 2025 | ▼ 382.7K |
CITADEL ADVISORS LLC biological products, (no diagnostic substances) | 13.97M | 6.38% | 6.38% | $17.32B | Nov 14, 2025 | ▲ 3.72M |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 9.02M | 4.12% | 4.12% | $11.19B | Nov 7, 2025 | ▲ 761.6K |
PRIMECAP MANAGEMENT CO/CA/ biological products, (no diagnostic substances) | 7.08M | 3.23% | 3.23% | $8.78B | Nov 12, 2025 | ▲ 1.36M |
WOODLINE PARTNERS LP biological products, (no diagnostic substances) | 4.36M | 1.99% | 1.99% | $5.41B | Nov 14, 2025 | — held |
FRAZIER LIFE SCIENCES MANAGEMENT, L.P. biological products, (no diagnostic substances) | 3.87M | 1.77% | 1.77% | $4.80B | Nov 14, 2025 | — held |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 3.83M | 1.75% | 1.75% | $4.75B | Nov 12, 2025 | ▲ 39.1K |
PRICE T ROWE ASSOCIATES INC /MD/ biological products, (no diagnostic substances) | 3.68M | 1.68% | 1.68% | $4.56B | Nov 14, 2025 | ▼ 353.4K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
27
Increased
+19.73M shares2
New Positions
first time holders13
Decreased
−16.80M shares0
Sold Out
fully exitedNet shares change (top 50)
+2.93M
+19.73M / −16.80M
Net new holders
+16
2 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
ALLO insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
0
Buy transactions
1
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Yoshiyama Annie SVP, Finance | Apr 21, 2026 | Sale | 9,586 | $2.31 | $22.1K | 124.5K | Form 4 ↗ |
Beneski Benjamin Machinas SVP, Chief Technical Officer | Mar 31, 2026 | Sale | 2,867 | $2.50 | $7.2K | 195.3K | Form 4 ↗ |
Beneski Benjamin Machinas SVP, Chief Technical Officer | Mar 16, 2026 | Sale | 4,835 | $2.47 | $11.9K | 198.2K | Form 4 ↗ |
Chang David D President and CEO | Mar 16, 2026 | Sale | 47,763 | $2.47 | $118.0K | 5.15M | Form 4 ↗ |
Beneski Benjamin Machinas SVP, Chief Technical Officer | Mar 2, 2026 | Sale | 7,132 | $2.60 | $18.5K | 203.0K | Form 4 ↗ |
Beneski Benjamin Machinas SVP, Chief Technical Officer | Feb 2, 2026 | Award | 373,757 | $1.87 | $698.9K | 373.8K | Form 4 ↗ |
Beneski Benjamin Machinas SVP, Chief Technical Officer | Feb 2, 2026 | Sale | 7,549 | $1.73 | $13.1K | 210.2K | Form 4 ↗ |
Chang David D President and CEO | Feb 2, 2026 | Sale | 95,269 | $1.80 | $171.5K | 5.19M | Form 4 ↗ |
Chang David D President and CEO | Feb 2, 2026 | Award | 1,387,931 | $1.87 | $2.60M | 1.39M | Form 4 ↗ |
Parker Geoffrey M. CHIEF FINANCIAL OFFICER | Feb 2, 2026 | Sale | 24,001 | $1.76 | $42.2K | 1.25M | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Allogene Therapeutics, Inc. (ALLO) is primarily owned by institutional investors, who hold approximately 66.6% of total shares outstanding. Company insiders own approximately 33.47%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Allogene Therapeutics, Inc. is PFIZER INC, holding approximately 22.03 million shares — equal to 10.06% of outstanding shares — as of September 30, 2025.
A total of 176 institutional investors currently hold ALLO stock, with a combined institutional value of approximately $201,515,758 as of the most recent 13F filing period.
Frequently asked questions
ALLO ownershipAllogene Therapeutics, Inc. (ALLO) is primarily owned by institutional investors, who hold approximately 66.6% of shares. The largest shareholder is PFIZER INC with a 10.06% stake. Company insiders hold 33.47%. Data sourced from SEC Form 13F as of September 30, 2025.